Our Clinical Approach to Stem Cell Therapy

Every clinical philosophy is, in the end, a set of decisions about what the clinician will refuse to do. Ours is no different. Regenerative medicine — and stem cell therapy inside it — sits at a strange intersection: a field with twenty-five years of basic-science publication behind it, a regulatory environment that is still catching up to the clinical reality, and a patient population that is often arriving after years of failed conventional care. That combination of real promise, partial evidence, and high patient hope is the exact set of conditions that produces both the most interesting medicine and the most predatory marketing.

Our first-principle position is that the right framing for stem cell therapy is not "miracle cure" and not "snake oil". It is a clinical tool with specific, measurable biological effects, useful in specific indications, and best deployed inside a multi-system regenerative plan that also addresses inflammation, metabolism, movement, and sleep. The plan around the cells is at least as important as the cells themselves. A patient who receives an MSC infusion into a chronic inflammatory environment driven by visceral adiposity, poor sleep, and untreated insulin resistance is unlikely to get the same response as one who receives the same infusion after twelve weeks of metabolic optimization. The science of stem cells is real. So is the science of the host that receives them.

Everything that follows — how we evaluate candidates, how we design protocols, what we promise, what we refuse to promise — derives from that first principle. Read it that way and the rest of the page is internally consistent. Read it as a sales page and it will feel oddly restrained, because that is exactly what it is meant to be.

The public image of stem cell therapy was largely formed by a generation of media headlines about "regrowing organs" and "reversing aging". That framing is, charitably, fifteen years out of date. The mechanism by which the most commonly used clinical product — mesenchymal stem cells (MSCs), typically from umbilical cord tissue, placenta, or adipose — exerts its therapeutic effect is not differentiation into new tissue. It is paracrine signaling: the MSCs secrete a cocktail of cytokines, growth factors, and extracellular vesicles (including exosomes) that modulate the local immune environment, dampen excessive inflammation, recruit endogenous repair cells, and shift the wound-healing program from chronic to resolving.

In simpler language: the MSCs are not the bricklayers. They are the foremen. They tell the body's own repair machinery — which is often dysregulated in chronic inflammatory and degenerative disease — to start behaving like a younger, more orderly version of itself. That mechanism explains why MSC therapy can help osteoarthritic knees (the joint is a local inflammatory environment that responds to immunomodulation), certain autoimmune conditions (where dialing down a chronically over-active immune response is exactly the clinical goal), and some post-injury or post-surgical recovery contexts (where the resolution-phase of inflammation has stalled).

It also explains why MSC therapy is genuinely unlikely to do what a sales page might promise it can — and we will name those limits explicitly in a later section. The mechanism is real, characterized, and reproducible. The mechanism also has a ceiling. Both facts have to live in the same sentence for the clinical reasoning to be honest.

It would be easier to write this section if regenerative medicine in 2026 were either fully validated or fully discredited. It is neither. The state of the field, as we read it, is roughly this: the basic science is mature, the mechanism is well-characterized, and large registries of clinical use exist. The randomized controlled trial evidence is strong for some indications, moderate for others, and absent or very preliminary for many of the conditions that are most aggressively marketed. A serious clinic has to be specific, by indication, about where on that spectrum a given patient sits.

Where the evidence is strongest: osteoarthritis of the knee, certain autoimmune conditions (graft-versus-host disease, ARDS in the inflammatory phase, some rheumatologic conditions), and post-surgical recovery in select orthopedic contexts. In these indications the published literature includes randomized trials, dose-response data, and durable follow-up. Where the evidence is moderate: chronic tendinopathies, certain post-injury knee and shoulder protocols when combined with appropriate rehabilitation, anti-inflammatory adjunct in metabolic dysfunction, and some neuro-inflammatory contexts where MSC immunomodulation has a plausible mechanism and case-series support but RCT data is still emerging. Where the evidence is preliminary or absent: most "anti-aging" indications as marketed, most cognitive-decline indications outside of specific inflammatory phenotypes, and any framing that promises tissue regeneration in late-stage degenerative disease.

We hold ourselves to that spectrum. A patient asking us about knee osteoarthritis is in a different evidence neighborhood than a patient asking us about late-stage neurodegeneration, and our answer has to reflect that difference. The temptation, especially in medical tourism, is to flatten the difference and offer the same protocol to everyone. We try not to.

Over the past two years roughly thirty percent of the inquiries we have received have not become patients. Some of those declines were patient-driven — the timing was wrong, the financing did not fit, the city was inconvenient. The remainder were declined by us, after medical review. Active malignancy, recent malignancy in remission outside our consensus window, uncontrolled infection, pregnancy, certain blood disorders, certain immune-modulating medications, and certain clinical phenotypes where the published evidence base does not support MSC therapy in that indication — each of these is a reason a candidate does not move forward, and each of those declines has been written down by a physician.

We mention the number — thirty percent — not as a marketing claim but as a measurement of intake hygiene. A clinic that has never declined a candidate is a clinic where the medical evaluation is downstream of the sale, and that is precisely the structural problem we have organized the practice to avoid. The medical review comes before any treatment quote is issued, because the order of those two events determines, in practice, the kind of clinic the patient is about to engage with.

The framework for candidacy is conservative. We ask: is there a published evidence base for MSC therapy in this indication that justifies offering it? Is the patient medically fit for the proposed protocol? Are there contraindications? What is the realistic expected response, and is the patient making the decision with that realistic expectation in writing, in a language they read fluently? If any of those four questions cannot be answered affirmatively, the candidate does not move forward, regardless of how strong their interest is. This is exactly the moment where a clinic's structure shows.

Protocol design in regenerative medicine is where most of the field's variability shows up. Two clinics can both "do MSC therapy" and run completely different operations: one might offer a flat 100-million-cell intravenous infusion to every patient regardless of indication or body weight; another might quote individualized cells-per-kilogram dosing, indication-specific routes (intravenous, intra-articular, intrathecal), and varying session counts based on the patient's response. The first version is a product. The second is medicine. Patients have a right to know which one they are buying.

Our protocol design starts from the indication, not from the catalog. For systemic immunomodulation we use cells-per-kilogram dosing in the 1–2 million cells/kg range — a number that derives from the published literature and is documented in the chart before the infusion. For local intra-articular delivery in knee osteoarthritis, the protocol is image-guided, often combined with PRP for the synovial environment, and tied to a rehabilitation program before and after. For post-surgical or post-injury orthopedic contexts, the protocol may be staged, with serial dosing or combination with peptide and IV adjunct therapies depending on the case. Every component is documented, sequenced, and signed by the treating physician.

The monitoring program is the second half of protocol design. Follow-up check-ins at one, three, six, and twelve months are scheduled, not optional. Outcome metrics — joint-specific questionnaires (KOOS, WOMAC) for osteoarthritis, condition-appropriate composites for autoimmune indications, patient-reported function for many orthopedic cases — are tracked and shared with the patient at each check-in. A protocol without a measurement plan is a transaction; a protocol with one is a course of treatment. We design every plan to be the second.

Language matters more in medicine than in almost any other domain, because it shapes the patient's expectations and therefore their experience of the treatment outcome. The words "cure", "reversal", and "regeneration" each carry specific implications, and using them loosely is one of the most reliable warning signs of a sales-led rather than medicine-led clinic.

A cure means the disease is resolved and does not return. For most of the chronic indications that bring patients to regenerative medicine — osteoarthritis, autoimmune conditions, chronic tendinopathies — that is not the realistic outcome of any current therapy, including stem cells. The realistic outcomes are, in order of likelihood: meaningful symptom reduction, measurable functional improvement, slower progression of the underlying disease, and in some cases reduction of medication burden. Each of these is a legitimate clinical win, and several of them are documented response patterns in the published MSC literature. None of them is a cure, and we will not use the word.

Beyond the language, the substantive point is that pretending the result will be a cure sets up the patient for one of two failure modes: either they discontinue their other care prematurely ("the stem cells will take care of it"), which can be medically harmful, or they experience the realistic-but-not-curative outcome as a failure ("I still have pain, so it didn't work"), which is unfair to the actual clinical benefit they may have received. Both failure modes are downstream of a single sentence that should never have been said. We try not to say it.

A clinic that takes the published evidence seriously is, in principle, a clinic that should contribute to it. We collect outcome data on every patient, with explicit consent, in a structured way that allows it to be aggregated into cohort-level analyses. We participate in industry-academic collaborations where the methodology is sound and the patient incentives are aligned. We publish what we learn — in clinical-meeting abstracts, in case series, and where possible in peer-reviewed papers — under our actual physician names and with full disclosure of conflicts.

The reason is not marketing. The reason is that an evidence-based field requires evidence, and the evidence has to be produced somewhere. Most of the MSC literature still comes from academic centers in a handful of countries; the contribution from clinical practice in Latin America, in the very patient populations who increasingly use Mexican regenerative clinics, is underrepresented. A serious clinic in this region is structurally positioned to add to the picture. We try to take that responsibility seriously, with the methodological humility that the data sometimes demands.

Patients have the right to opt in or out of any data collection, and the data we collect is de-identified for any aggregate analysis. The opt-in form is reviewed at intake, separately from the consent for treatment, so that no patient feels pressured to consent to one in order to receive the other. The research participation is a permission the patient grants, not a default they have to opt out of after the fact.

The regenerative medicine field has a steady stream of "next thing" candidates — exosomes, peptide combinations, molecular hydrogen, plasma exchange, NAD-precursor stacks, senolytics. Each of these has a real biological basis. Each of them is at a different point on the evidence spectrum, and each of them has been over-marketed by some clinics and under-investigated by others. The clinic's job is to make a sober, case-by-case decision about which of them deserves a place in the protocol — and that decision should look the same regardless of which is currently in fashion.

Our framework: does the therapy have a characterized mechanism? Does it have published clinical evidence in the indication where we would consider using it? Is it sourced from a regulated and verifiable supply chain? Does it have a reasonable risk profile in the patient population we are considering? If yes to all four, we may include it as an adjunct in a personalized protocol — with explicit, written disclosure to the patient about the evidence basis. If no to any, we do not.

That framework has, in practice, led us to use some emerging tools (exosomes for selected aesthetic and orthopedic indications, certain peptides as part of a broader regenerative program) and to decline others (molecular hydrogen as a primary intervention, several NAD-stack protocols that we have not seen credible cohort data for, certain senolytic combinations that the published evidence does not yet support in human cohorts). The list will shift over time as evidence accumulates. The framework will not.

There is a category of clinic in regenerative medicine that has built its operation around a specific patient state: late-stage disease, prior failed therapies, and a willingness to spend significant out-of-pocket sums on hope. That patient state is a real, human condition — desperation in the face of an illness that conventional medicine could not resolve — and a serious clinical operation has to start by acknowledging that the patient sitting across the desk often arrived at the regenerative-medicine door by way of a long series of disappointments.

The ethical problem is what happens next. A clinic that sees that patient state primarily as a commercial opportunity will design its intake, its messaging, and its pricing around extracting the maximum revenue from that hope. A clinic that sees that patient state primarily as a medical responsibility will design the same operations around tempering the hope to match the actual evidence base, declining patients for whom the evidence does not support treatment, and using language that is consistent with realistic outcomes. The two clinics look identical from the website. They look very different inside the consultation room.

We try to be the second. That is the entire ethical argument compressed into a sentence, and it is also why a page like this one exists — not as marketing, but as a publicly available statement of how we conduct the practice, so that a patient who chooses us is choosing knowingly. When the patient population is in the most vulnerable state of their medical lives, the integrity of the clinic becomes a feature of the medicine, not a soft skill around the edges of it.

It is easier to describe the practice by what it refuses than by what it offers, because the refusals are where the structural choices live. We do not promise cures. We do not quote a treatment price before a physician has reviewed the patient's records. We do not let non-medical staff lead the clinical conversation. We do not have a same-day-discount sales tactic. We do not run a one-size-fits-all protocol that ignores indication, body weight, or comorbidity. We do not offer therapies whose mechanism we cannot characterize or whose evidence base we cannot point to. We do not market a treatment for an indication that is not on our internal published evidence map. We do not pretend MSC therapy regenerates organs in late-stage degenerative disease. We do not let the patient sign a treatment consent without a written, itemized quote and a protocol summary in a language they read fluently.

Each of these refusals has cost us patients in the short term. They have also, over a longer horizon, produced the patient base we actually want — patients who arrived having done the homework, who understood the realistic outcome before they committed, and who became advocates not because the marketing told them to but because the experience matched the description. That patient base is, in practice, the strongest validation of the model.

The positive form of the same description: we offer evidence-based, physician-led, individualized regenerative protocols, in a COFEPRIS-regulated facility, with named physicians, written documentation, structured follow-up, and an outcomes-tracking program. None of that should be remarkable. In a field as visible as this one, it is.